ClinVar Miner

Submissions for variant NM_032043.2(BRIP1):c.550G>T (p.Asp184Tyr) (rs201047375)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000132540 SCV000187637 uncertain significance Hereditary cancer-predisposing syndrome 2018-05-02 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence
Color RCV000132540 SCV000684286 uncertain significance Hereditary cancer-predisposing syndrome 2018-06-06 criteria provided, single submitter clinical testing
Counsyl RCV000662870 SCV000785762 uncertain significance Fanconi anemia, complementation group J; Neoplasm of ovary 2017-11-29 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000168177 SCV000895116 uncertain significance Familial cancer of breast; Fanconi anemia, complementation group J 2018-10-31 criteria provided, single submitter clinical testing
GeneDx RCV000212302 SCV000210820 uncertain significance not provided 2018-12-11 criteria provided, single submitter clinical testing This variant is denoted BRIP1 c.550G>T at the cDNA level, p.Asp184Tyr (D184Y) at the protein level, and results in the change of an Aspartic Acid to a Tyrosine (GAT>TAT). This variant has been observed in at least one individual with a personal history of a Lynch syndrome-associated cancer and/or polyps and one individual with sarcoma (Yurgelun 2015, Ballinger 2016). Additionally, BRIP1 Asp184Tyr has been observed in males and females with breast cancer, but has also been observed in control populations (Lu 2015, Ramus 2015, Easton 2016, Shirts 2016, Rummel 2017, Fostira 2018). Vel?zquez et al. (2018) reported that this variant results in exon 5 skipping due to creation of a splice enhancer site. BRIP1 Asp184Tyr was observed at an allele frequency of 0.02% (28/126622) in individuals of European ancestry in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether BRIP1 Asp184Tyr is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
GeneKor MSA RCV000132540 SCV000821966 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
Invitae RCV000168177 SCV000218840 uncertain significance Familial cancer of breast; Fanconi anemia, complementation group J 2018-11-30 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid with tyrosine at codon 184 of the BRIP1 protein (p.Asp184Tyr). The aspartic acid residue is highly conserved and there is a large physicochemical difference between aspartic acid and tyrosine. This variant is present in population databases (rs201047375, ExAC 0.03%). This variant has been observed in individuals affected with breast cancer and Lynch syndrome-associated cancers, as well as healthy individuals (PMID: 26845104, 28503720, 26921362, 25186627, 30230034, 29368626, 25980754). In one of these individuals affected with breast cancer, a pathogenic allele was also identified in BRIP1, which suggests that this c.550G>T variant was not the primary cause of disease. (Invitae). ClinVar contains an entry for this variant (Variant ID: 143021). Experimental studies have shown that this variant results in exon 5 skipping (PMID: 30230034). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
University of Washington Department of Laboratory Medicine,University of Washington RCV000132540 SCV000266160 uncertain significance Hereditary cancer-predisposing syndrome 2015-11-20 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.